Yaron Conforti on Psychedelic Medicine Today and 10 Years from Now
Novamind CEO talks with PsyFi about the future of healthcare and the spectrum of alternative services available today in our clinics.
Bringing New Hope to a State Struggling with Mental Illness
The Daily Utah Chronicle speaks with Novamind’s CMO, Dr. Reid Robison, on the game-changing effects of psychedelic-assisted therapy.
Novamind’s Project with Merck Another Example of Its Research Leadership
Up to 80 million people suffer from treatment-resistant depression and we’re proud to work with one of the most recognized pharmaceutical names in the world to study an alternative.
Yaron Conforti Discusses Partnership with Merck for New Treatment-Resistant Depression Trial
Novamind's CEO talks with George Tsiolis from Agoracom about his excitement to advance research for innovative mental health treatments.
Why Merck Chose Novamind for a New Clinical Trial
Our deep experience hosting clinical trials and treating depression drew Merck to test a new drug aimed at treatment-resistant depression.
Yaron Conforti on Democratizing Access to Psychedelic Medicine
CEO and Director Yaron Conforti talks with Paul Austin, founder of Third Wave, about how Novamind provides safe, legal access to psychedelic medicine today.